 "Covid-19: BDR Pharmaceuticals plans to launch 400 mg Favipiravir tablets")
Drug firm BDR Pharmaceuticals on Friday said it plans to launch 400 mg Favipiravir tablets, used for treating Covid-19 patients, in the country.
The 'BDFAVI' 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99. In August, the company launched 200 mg Favipiravir tablets.
"We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis... introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers," BDR Pharma CMD Dharmesh Shah said.
The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate Covid-19 symptoms under the brand name BDFAVI, according to the statement.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%